Patient-reported pregnancy loss and maternal complications: Insights from the sickle cell disease implementation consortium.
fertility
pregnancy
pregnant women
sickle cell
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
revised:
17
09
2024
received:
25
05
2024
accepted:
07
10
2024
medline:
25
10
2024
pubmed:
25
10
2024
entrez:
25
10
2024
Statut:
aheadofprint
Résumé
Sickle cell disease (SCD) is associated with complications during pregnancy and can negatively influence maternal outcomes. Our study aimed to determine the prevalence and predictors of maternal morbidity among participants enrolled in an eight-site SCD Implementation Consortium (SCDIC) registry. We conducted a cross-sectional analysis of female registry participants, aged 15-45 years, with a confirmed diagnosis of SCD. Participants completed a survey of self-reported pregnancies and outcomes. Seven hundred and thirty-eight individuals had at least one pregnancy event, with 1076 live births. Twenty percent reported a pregnancy loss or fetal demise. Of the 1076 live births, 75% involved at least one complication. The most prevalent complications were pain crises (61.1%) and pregnancy requiring blood transfusion(s) (33.0%). Multiparous individuals with a prior occurrence of a complication in a previous pregnancy had higher odds of recurrence of the same complication in subsequent pregnancies (i.e., previous acute crisis was associated with subsequent acute pain events odds ratio [OR]: 3.13; 95% confidence interval [CI]: 2.06-4.76) and prior transfusion requiring another transfusion (OR: 3.22; 95% CI: 2.01-5.16). Individuals reported a high prevalence of pregnancy loss and maternal complications. Our findings underscore the importance of preconception counseling and early initiation of perinatal care in SCD.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI Division of Intramural Research
ID : 3U01HL133964-04S1
Organisme : NHLBI Division of Intramural Research
ID : U24HL133948
Organisme : NHLBI Division of Intramural Research
ID : U01HL133964
Organisme : NHLBI Division of Intramural Research
ID : U01HL133990
Organisme : NHLBI Division of Intramural Research
ID : U01HL133996
Organisme : NHLBI Division of Intramural Research
ID : U01HL133994
Organisme : NHLBI Division of Intramural Research
ID : U01HL133997
Organisme : NHLBI Division of Intramural Research
ID : U01HL134004
Organisme : NHLBI Division of Intramural Research
ID : U01HL134007
Organisme : NHLBI Division of Intramural Research
ID : U01HL134042
Informations de copyright
© 2024 International Federation of Gynecology and Obstetrics.
Références
Hassell KL. Population estimates of sickle cell disease in the U.S. Am J Prev Med. 2010;38(4):S512‐S521. doi:10.1016/j.amepre.2009.12.022
Kato GJ, Hebbel RP, Steinberg MH, Gladwin MT. Vasculopathy in sickle cell disease: biology, pathophysiology, genetics, translational medicine and new research directions. Am J Hematol. 2009;84(9):618‐625. doi:10.1002/ajh.21475
National Heart, Lung, and Blood Institute (NHLBI). Evidence‐Based Management of Sickle Cell Disease: Expert Panel Report, 2014|National Heart, Lung, and Blood Institute (NHLBI). Accessed Jan 20, 2020. https://www.nhlbi.nih.gov/health‐topics/all‐publications‐and‐resources/evidence‐based‐management‐sickle‐cell‐disease‐expert‐0
Oteng‐Ntim E, Meeks D, Seed PT, et al. Adverse maternal and perinatal outcomes in pregnant women with sickle cell disease: systematic review and meta‐analysis. Blood. 2015;125(21):3316‐3325. doi:10.1182/blood-2014-11-607317
Soma‐Pillay P, Catherine N‐P, Tolppanen H, Mebazaa A, Tolppanen H, Mebazaa A. Physiological changes in pregnancy. Cardiovasc J Afr. 2016;27(2):89‐94. doi:10.5830/CVJA-2016-021
James AH, Strouse JJ. How we treat sickle cell disease in pregnancy. Blood. 2023;143:769‐776. doi:10.1182/blood.2023020728
Early ML, Eke AC, Gemmill A, Lanzkron S, Pecker LH. Severe maternal morbidity and mortality in sickle cell disease in the National Inpatient Sample, 2012–2018. JAMA Netw Open. 2023;6(2):e2254552. doi:10.1001/jamanetworkopen.2022.54552
Kroner BL, Hankins JS, Pugh N, et al. Pregnancy outcomes with hydroxyurea use in women with sickle cell disease. Am J Hematol. 2022;97(5):603‐612. doi:10.1002/ajh.26495
DiMartino LD, Baumann AA, Hsu LL, et al. The sickle cell disease implementation consortium: translating evidence‐based guidelines into practice for sickle cell disease. Am J Hematol. 2018;93(12):E391‐E395. doi:10.1002/ajh.25282
Glassberg JA, Linton EA, Burson K, et al. Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry. Orphanet J Rare Dis. 2020;15(1):178. doi:10.1186/s13023-020-01457-x
Masese RV, DeMartino T, Bonnabeau E, et al. Effective recruitment strategies for a sickle cell patient registry across sites from the sickle cell disease implementation consortium (SCDIC). J Immigr Minor Health. 2021;23(4):725‐732. doi:10.1007/s10903-020-01102-6
Alayed N, Kezouh A, Oddy L, Abenhaim HA. Sickle cell disease and pregnancy outcomes: population‐based study on 8.8 million births. J Perinat Med. 2014;42(4):487‐492. doi:10.1515/jpm-2013-0275
Pecker LH, Sharma D, Nero A, et al. Knowledge gaps in reproductive and sexual health in girls and women with sickle cell disease. Br J Haematol. 2021;194(6):970‐979. doi:10.1111/bjh.17658
Dong M, Ware RE, Dallmann A, Vinks AA. Hydroxyurea treatment for sickle cell anemia during pregnancy and lactation: current evidence and knowledge gaps. Pharmacother J Hum Pharmacol Drug Ther. 2023;43(5):419‐429. doi:10.1002/phar.2793
Malinowski AK, Shehata N, D'Souza R, et al. Prophylactic transfusion for pregnant women with sickle cell disease: a systematic review and meta‐analysis. Blood. 2015;126(21):2424‐2435. doi:10.1182/blood-2015-06-649319
Adesina OO, Brunson A, Fisch SC, et al. Pregnancy outcomes in women with sickle cell disease in California. Am J Hematol. 2023;98(3):440‐448. doi:10.1002/ajh.26818
Asare EV, Olayemi E, Boafor T, et al. Implementation of multidisciplinary care reduces maternal mortality in women with sickle cell disease living in low‐resource setting. Am J Hematol. 2017;92(9):872‐878. doi:10.1002/ajh.24790
Oppong SA, Asare EV, Olayemi E, et al. Multidisciplinary care results in similar maternal and perinatal mortality rates for women with and without SCD in a low‐resource setting. Am J Hematol. 2019;94(2):223‐230. doi:10.1002/ajh.25356
Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Lancet. 2017;390(10091):311‐323. doi:10.1016/s0140-6736(17)30193-9
Savage NM, Nugent WF, Devoe LD, Bollag RJ, Cook LO. Transfusion considerations concerning patients with anti‐hrB and confounding co‐morbid conditions: pregnancy and coagulopathy. Blood Transfus. 2011;9(2):225‐229. doi:10.2450/2010.0029-10
DeBaun MR, Jordan LC, King AA, et al. American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults. Blood Adv. 2020;4(8):1554‐1588. doi:10.1182/bloodadvances.2019001142
Studnicki J, Fisher JW, Reardon DC, Craver C, Longbons T, Harrison DJ. Pregnancy outcome patterns of Medicaid‐eligible women, 1999–2014: a National Prospective Longitudinal Study. Health Serv Res Manag Epidemiol. 2020;7:2333392820941348. doi:10.1177/2333392820941348
Whitley E, Doyle P, Roman E, De Stavola B. The effect of reproductive history on future pregnancy outcomes. Hum Reprod. 1999;14(11):2863‐2867. doi:10.1093/humrep/14.11.2863
Sinkey RG, Ogunsile FJ, Kanter J, Bean C, Greenberg M. Society for Maternal‐Fetal Medicine Consult Series #68: sickle cell disease in pregnancy. Am J Obstet Gynecol. 2024;230(2):B17‐B40. doi:10.1016/j.ajog.2023.10.031
Faye BF, Kouame KB, Seck M, et al. Challenges in the management of sickle cell disease during pregnancy in Senegal, West Africa. Hematology. 2018;23(1):61‐64. doi:10.1080/10245332.2017.1367534
Adeyemi AB, Adediran IA, Kuti O, Owolabi AT, Durosimi MA. Outcome of pregnancy in a population of Nigerian women with sickle cell trait. J Obstet Gynaecol. 2006;26(2):133‐137. doi:10.1080/01443610500443428
Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98(5):1103‐1111. doi:10.1016/j.fertnstert.2012.06.048
Strumpf E, Lang A, Austin N, et al. Prevalence and clinical, social, and health care predictors of miscarriage. BMC Pregnancy Childbirth. 2021;21(1):185. doi:10.1186/s12884-021-03682-z
Mukherjee S, Velez Edwards DR, Baird DD, Savitz DA, Hartmann KE. Risk of miscarriage among black women and white women in a US prospective cohort study. Am J Epidemiol. 2013;177(11):1271‐1278. doi:10.1093/aje/kws393
Quenby S, Gallos ID, Dhillon‐Smith RK, et al. Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss. Lancet Lond Engl. 2021;397(10285):1658‐1667. doi:10.1016/S0140-6736(21)00682-6
Oteng‐Ntim E, Ayensah B, Knight M, Howard J. Pregnancy outcome in patients with sickle cell disease in the UK—a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. Br J Haematol. 2015;169(1):129‐137. doi:10.1111/bjh.13270